�A year of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members.
"We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market," pen Sonal Singh, M.D., M.P.H., assistant prof of internal medicine, and Curt D. Furberg, M.D., Ph.D., professor of populace health sciences. Rosiglitazone and pioglitazone are the iI major thiazolidinediones.
In the editorial Singh and Furberg say, "At this time, justification for role of thiazolidinediones is identical weak to non-existent."
Oral drugs are granted to control diabetes by lowering origin sugar.
But diabetics also live elevated rates of high blood pressure and high levels of cholesterol and triglyceride, which "further compound their already increased risk of development ischemic ticker disease," Singh and Furberg say. Heart disease and high ancestry pressure "represent conditions that are major precursors of congestive fondness failure."
About 22 percent of diabetics have heart disease. Among aged patients with diabetes, more than half will develop congestive marrow failure
